Evidence map›Paper›PMID 24693336›Full record

ReviewOxidative medicine and cellular longevity2014

Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases.

Yonggang Wang, Xiao Miao, Yucheng Liu, Fengsheng Li, Quan Liu, Jian Sun, Lu Cai

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oxidative medicine and cellular longevity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 117 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Yonggang WangCardiovascular Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China ; Department of Pediatrics, Kosair Children Hospital Research Institute, University of Louisville, 570 South Preston Street, Baxter I, Suite 304F, Louisville, KY 40202, USA.
Xiao MiaoDepartment of Pediatrics, Kosair Children Hospital Research Institute, University of Louisville, 570 South Preston Street, Baxter I, Suite 304F, Louisville, KY 40202, USA ; The Second Hospital of Jilin University, Changchun 130041, China.
Yucheng LiuDepartment of Pediatrics, Kosair Children Hospital Research Institute, University of Louisville, 570 South Preston Street, Baxter I, Suite 304F, Louisville, KY 40202, USA.
Fengsheng LiDepartment of Pediatrics, Kosair Children Hospital Research Institute, University of Louisville, 570 South Preston Street, Baxter I, Suite 304F, Louisville, KY 40202, USA ; The Second Artillery General Hospital, Beijing 100088, China.
Quan LiuCardiovascular Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China.
Jian SunCardiovascular Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China.
Lu CaiDepartment of Pediatrics, Kosair Children Hospital Research Institute, University of Louisville, 570 South Preston Street, Baxter I, Suite 304F, Louisville, KY 40202, USA.
Jilin University · CNUniversity of Louisville · USKosair Children's Hospital · USSecond Affiliated Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) remains a leading cause of mortality worldwide despite advances in its prevention and management. A comprehensive understanding of factors which contribute to CVD is required in order to develop more effective treatment options. Dysregulation of epigenetic posttranscriptional modifications of histones in chromatin is thought to be associated with the pathology of many disease models, including CVD. Histone acetyltransferases (HATs) and deacetylases (HDACs) are regulators of histone lysine acetylation. Recent studies have implicated a fundamental role of reversible protein acetylation in the regulation of CVDs such as hypertension, pulmonary hypertension, diabetic cardiomyopathy, coronary artery disease, arrhythmia, and heart failure. This reversible acetylation is governed by enzymes that HATs add or HDACs remove acetyl groups respectively. New evidence has revealed that histone acetylation regulators blunt cardiovascular and related disease states in certain cellular processes including myocyte hypertrophy, apoptosis, fibrosis, oxidative stress, and inflammation. The accumulating evidence of the detrimental role of histone acetylation in cardiac disease combined with the cardioprotective role of histone acetylation regulators suggests that the use of histone acetylation regulators may serve as a novel approach to treating the millions of patients afflicted by cardiac diseases worldwide.

Indexed as

AcetylationAnimalsCardiovascular DiseasesHistone AcetyltransferasesHistone DeacetylasesHumansTranslational Research, BiomedicalHistone AcetyltransferasesHistone Deacetylases

Identifiers

PMID24693336
PMCPMC3945289
OpenAlexW2094272882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.